ESMO IO 2022 – Luca Mazzarella

Luca Mazzarella discusses the effects of modifying the pharmacology of anti-PD1 agents on their efficacy/toxicity in patients with advanced squamous NSCLC, explains potential therapeutic benefits of adding anti-CTLA4 or de-escalating chemotherapy to anti-PD1 blockade and highlights the role of individual or combined predictive biomarkers and biostatistics tools.

Here is the full ESMO IO 2022 Solid Tumors report.

More posts